Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

Lilly Finalizes Acquisition of ImClone Systems

  • Eli Lilly and Company completed its acquisition of ImClone Systems today. ImClone Systems is now a wholly owned subsidiary of Lilly.

    "We are excited about the successful completion of the ImClone transaction, which will broaden Lilly's portfolio of marketed cancer therapies and boost Lilly's oncology pipeline with up to three promising targeted therapies in Phase III in 2009," said John Lechleiter, Ph.D., Lilly president and CEO.

    ImClone's CEO, John Johnson, will retain his current position at ImClone after the acquisition and will report directly to Lechleiter.

     



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »